| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
7 |
| Employees |
32 |
| Revenues (TTM) (Millions $) |
37 |
| Net Income (TTM) (Millions $) |
17 |
| Cash Flow (TTM) (Millions $) |
-10 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Biospecifics Technologies Corp is a biopharmaceutical company that specializes in the development and commercialization of collagenase-based therapies for the treatment of various medical conditions. The company's core technology is based on the use of enzymes that selectively break down collagen, a protein that is a major component of connective tissues in the body.
Biospecifics Technologies Corp was founded in 1990 and its headquarters are located in Lynbrook, New York. The company is publicly traded on NASDAQ with the ticker symbol "BSTC".
The company's lead product is Xiaflex, a collagenase-based therapy that is FDA-approved for the treatment of Dupuytren's contracture, a condition that causes the fingers to curl inward towards the palm. Xiaflex is also FDA-approved for the treatment of Peyronie's disease, a connective tissue disorder that affects the penis.
In addition to Xiaflex, Biospecifics Technologies Corp is also developing collagenase-based therapies for the treatment of other conditions, including cellulite, frozen shoulder syndrome, and lipomas.
The company has a strong pipeline of products in development, including CCH for the treatment of cellulite and injectable collagenase for the treatment of Dupuytren's contracture.
Biospecifics Technologies Corp has a strong intellectual property portfolio, with numerous patents and patent applications relating to its collagenase-based technologies. The company has also entered into licensing agreements with several major pharmaceutical companies for the development and commercialization of its products.
Furthermore, the company has a proven track record of success with Xiaflex. In 2019, the company reported revenues of $119.5 million, a 19% increase from the previous year, driven by increased sales of Xiaflex.
Overall, Biospecifics Technologies Corp is a leading biopharmaceutical company with a strong focus on collagenase-based therapies. The company has a strong pipeline of products in development and a proven track record of success with Xiaflex. With a strong intellectual property portfolio and a growing market for its products, Biospecifics Technologies Corp is well-positioned for future growth and success in the biopharmaceutical industry.
Company Address: 2 Righter Parkway, Suite 200 Wilmington 19803 DE
Company Phone Number: 842.8450 Stock Exchange / Ticker: NASDAQ BSTC
|
%